Specific chemotherapy of Chagas disease: Controversies and advances

Trends in Parasitology

Volumn 19, Issue 11, 2003, Pages 495-501

  Urbina, Julio A ^a   Docampo, Roberto ^b  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ALBACONAZOLE; ALLOPURINOL; ANTIPARASITIC AGENT; BENZNIDAZOLE; BMS 207 147; CRA 3316; CRUZIPAIN INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; DIHYDROFOLATE REDUCTASE; ITRACONAZOLE; KETOCONAZOLE; MILTEFOSINE; NIFURTIMOX; NITROIMIDAZOLE; OXIDOSQUALENE CYCLASE INHIBITOR; OXIPURINOL; PHOSPHOLIPID; POSACONAZOLE; PURINE; PYRIMIDINE DERIVATIVE; PYROPHOSPHATE INHIBITOR; RAVUCONAZOLE; SPORONOX; SQUALENE SYNTHASE INHIBITOR; THIOSEMICARBAZONE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ACYLATION; ANOREXIA; CHAGAS DISEASE; CHEMOTHERAPY; CHRONIC DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; EPIDEMIOLOGICAL DATA; GOUT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OXIDATION REDUCTION REACTION; PARASITOSIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHOSPHOLIPID SYNTHESIS; PRENYLATION; REVIEW; SKIN ALLERGY; STEROL SYNTHESIS; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; VOMITING;

PROTOZOA; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 0142227145     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.09.001     Document Type: Review

References (57)

1. Morel C.M. Reaching maturity - 25 Years of the TDR. Parasitol. Today. 16:2000;522-525.
2. Schmuñis G.A. A Tripanossomíase Americana e seu impacto na suúde publica das Américas. Brener Z., et al. Trypanosoma cruzi e Doença de Chagas. 2000;1-15 Guanabara Koogan, Rio de Janeiro.
3. Control of Chagas Disease. Tech. Rep. Ser. 905:2002;1-109.
4. Vinhaes M.C., Schofield C.J. Trypanosomiasis control: surmounting diminishing returns. Trends Parasitol. 19:2003;112-113.
5. Brener Z., Gazzinelli R.T. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int. Arch. Allergy Immunol. 114:1997;103-110.
6. Kirchhoff L.V. Chagas disease (American Trypanosomiasis): a tropical disease now emerging in the United States. Scheld W.M., et al. Emerging Infections 3. 1999;111-134 ASM Press.
7. Tarleton R.L., Zhang L. Chagas disease ethiology: Autoimmunity or parasite persistence? Parasitol. Today. 15:1999;94-99.
8. Tarleton R.L. Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol. 31:2001;550-554.
9. Luquetti A.O. Etiological treatment of Chagas disease. The National Health Foundation of Brazil. Parasitol. Today. 13:1997;127-128.
10. Etiological treatment of Chagas disease. Rev. Pat. Trop. 28:1998;247-279.
11. Docampo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem. Biol. Interact. 73:1990;1-27.
12. Cançado J.R. Criteria of Chagas disease cure. Mem. Inst. Oswaldo Cruz. 94:(Suppl. 1):1999;331-336.
13. Andrade S.G., et al. Specific chemotherapy of Chagas' disease: a comparison between the response in patients and experimental animals infected with the same strains. Trans. R. Soc. Trop. Med. Hyg. 86:1992;624-626.
14. Bahia-Oliveira L.M.G., et al. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J. Infect. Dis. 182:2000;634-638.
15. Romanha A.J., et al. Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitological cure. J. Infect. Dis. 186:2002;823-828.
16. de Andrade A.L., et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 348:1996;1407-1413.
17. Sosa Estani S., et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am. J. Trop. Med. Hyg. 59:1998;526-529.
18. Sosa Estani S., Segura E.L. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines in Argentina. Mem. Inst. Oswaldo Cruz. 94:(Suppl. 1):1999;363-365.
19. Silveira C.A.N., et al. Avaliação do tratamiento especifico para o Trypanosoma cruzi en criaças, na evolucion da fase indeterminada. Rev. Soc. Bras. Med. Trop. 33:2000;191-196.
20. Solari A., et al. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3-year follow-up study. J. Antimicrob. Chemother. 48:2001;515-519.
21. Añez N., et al. Myocardial parasite persistence in chronic chagasic patients. Am. J. Trop. Med. Hyg. 60:1999;726-732.
22. Braga M.S., et al. Persistent infections in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev. Inst. Med. Trop. Sao Paulo. 42:2000;157-161.
23. Britto C., et al. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem. Inst. Oswaldo Cruz. 96:2001;823-826.
24. Lauria-Pires L., et al. Progressive chronic Chagas disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am. J. Trop. Med. Hyg. 63:2000;111-118.
25. Urbina J.A. Specific treatment of Chagas disease: current status and new developments. Curr. Opin. Infect. Dis. 14:2001;733-741.
26. Urbina J.A. Chemotherapy of Chagas disease. Curr. Pharm. Des. 8:2002;287-295.
27. Viotti R., et al. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J. 127:1994;151-162.
28. Docampo R. Recent developments in the chemotherapy of Chagas' disease. Curr. Pharm. Des. 7:2001;1157-1164.
29. Coura J.R., de Castro S.L. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz. 97:2002;3-24.
30. Apt W., et al. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. 59:1998;133-138.
31. Apt W., et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Ann. Trop. Med. Parasitol. 97:2003;23-29.
32. Urbina J.A., et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents. 21:2003;39-48.
33. Urbina J.A., et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents. 21:2003;27-38.
34. Urbina J.A., et al. In vitro antiproliferative effects and mechanism of action of the new triazole derivative ur-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44:2000;2498-2502.
35. Buckner F.S., et al. Potent anti-Trypanosma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob. Agents Chemother. 45:2001;1210-1215.
36. Urbina J.A., et al. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol. Biochem. Parasitol. 125:2002;35-45.
37. Urbina J.A. New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis). Expert Opin. Ther. Pat. 13:2003;661-669.
38. Cazzulo J.J., et al. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. Curr. Pharm. Des. 7:2001;1143-1156.
39. Caffrey C.R., et al. Cysteine proteinases of Trypanosoma parasites: novel targets for chemotherapy. Curr. Drug Targets. 1:2000;155-162.
40. Engel J.C., et al. Cysteine protease inhibitors cure experimental Trypanosma cruzi infection. J. Exp. Med. 188:1998;725-734.
41. Du X., et al. Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. 45:2002;2695-2707.
42. Docampo R., Moreno S.N.J. The acidocalcisome. Mol. Biochem. Parasitol. 33:2001;151-159.
43. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science. 289:2000;1508-1514.
44. Montalvetti A., et al. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem. 276:2001;33930-33937.
45. Docampo R., Moreno S.N.J. Bisphosphonates as chemotherapeutic agents against Trypanosomatid and Apicomplexan parasites. Curr. Drug Targets Infect. Disord. 1:2001;51-61.
46. Stoppani A.O.M. Quimioterapia de la Enfermedad de Chagas. Medicina. 59:(Suppl. 2):1999;147-165.
47. Lauria-Pires L., et al. Ineffectiveness of allopurinol in patients in the acute phase of Chagas disease. Rev. Soc. Bras. Med. Trop. 21:1988;79.
48. World Health Organization (1995) Tropical disease research. In Twelfth Programme Report, UNDP/World Bank/World Health Organization Programme for Research and Training in Tropical Diseases, pp. 129-133, World Health Organization.
49. Freymann D.M., et al. Efficient incorporation of inhibitors targeting the closed active site conformation of HPRT from Trypanosoma cruzi. Chem. Biol. 7:2000;957-968.
50. Schmidt A., Krauth-Siegel R.L. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr. Top. Med. Chem. 2:2002;1239-1259.
51. Gilbert I.H. Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Biochim. Biophys. Acta. 587:2002;249-257.
52. Saraiva V.B., et al. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob. Agents Chemother. 46:2002;3472-3477.
53. Gelb M.H., et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. 126:2003;155-163.
54. Kalil J., Cunha-Neto E. Autoimmunity in Chagas disease cardiomyopathy: fullfilling the criteria at last? Parasitol. Today. 12:1996;396-399.
55. Engman D.M., Leon J.S. Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop. 81:2002;123-132.
56. Urbina J.A. Parasitological cure of Chagas Disease: is it possible? Is it relevant? Mem. Inst. Oswaldo Cruz. 94:(Suppl. 1):1999;349-355.
57. Perez-Fuentes R., et al. Severity of chronic Chagas disease is associated with cytokine/antioxidant imbalance in chronically infected individuals. Int. J. Parasitol. 33:2003;293-299.